Annotation Detail
Information
- Associated Genes
- NRAS
- Associated Variants
-
NRAS MUTATION
NRAS MUTATION - Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). Among 8 patients with NRAS mutated melanoma, 4 experienced SD or PR (1 Patient received study treatment for 323 days).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/996
- Gene URL
- https://civic.genome.wustl.edu/links/genes/36
- Variant URL
- https://civic.genome.wustl.edu/links/variants/208
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Supports
- Drug
- MEK Inhibitor RO4987655
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24947927
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| MEK Inhibitor RO4987655 | Sensitivity | true |